# CT-388

Canonical source: https://retacompare.com/encyclopedia/ct-388

Once-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.

Reference facts

Also known asCarmot CT-388CategoryGLP-1 & MetabolicMechanism of actionOnce-weekly dual GLP-1 / GIP agonist with biased GLP-1 signaling profile.TargetsGLP-1R, GIPRIndications under research or approvedObesity, Type 2 DiabetesRegulatory status (reference entry)Investigational (Phase 2)Half-life~7 daysSequence notesDual GLP-1 / GIP receptor agonist with proprietary lipid-stalk modification; Roche acquired Carmot 2023.Originator / sponsorRoche (Carmot Therapeutics)First reported2023
    Primary References

CT-388 Phase 1 obesity (NCT04838405)


    Explore research articles about CT-388


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- CT-388 Phase 1 obesity (NCT04838405): https://clinicaltrials.gov/study/NCT04838405